#obesity-drug

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo Nordisk's experimental obesity drug, CagriSema, demonstrated a significant 25% weight loss in women during late-stage analysis, surpassing the efficacy of its blockbuster drug Wegovy. This breakthrough suggests a potential new standard in obesity treatment, offering improved outcomes for patients.